Diabetes Treatment Report

www.DiabetesTreatmentReport.com

Research

Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device

https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00338-4

Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device
A.M. James Shapiro
David Thompson
Thomas W. Donner
Evert J. Kroon
Kevin A. D’Amour
Howard L. Foyt 9
Show all authors
Show footnotes
Open AccessPublished:December 02, 2021DOI:https://doi.org/10.1016/j.xcrm.2021.100466

Initial data suggest that pluripotent stem cells, which can be propagated to the desired biomass and differentiated into pancreatic islet-like tissue, may offer a scalable, renewable alternative to pancreatic islet transplants.

Evolving Antibody Therapies for the Treatment of Type 1 Diabetes

https://pubmed.ncbi.nlm.nih.gov/33679717/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1bQr69UjXVaRRUWkFKIzHYhAULOEOHnEnNj24W3oISCxcPMYuA&fc=None&ff=20210308072436&v=2.14.2

TITLE:
Evolving Antibody Therapies for the Treatment of Type 1 Diabetes

DESCRIPTION:
Type 1 diabetes (T1D) is widely considered to be a T cell driven autoimmune disease resulting in reduced insulin production due to dysfunction/destruction of pancreatic β cells. Currently, there continues to be a need for immunotherapies that selectively reestablish persistent β cell-specific self-tolerance for the prevention and remission of T1D in the clinic. The utilization of monoclonal antibodies (mAb) is one strategy to target specific immune cell populations inducing autoimmune-driven…

PMID:
pubmed:33679717

DATE FOUND:
03/08/21 07:35AM

LINK / URL:
https://pubmed.ncbi.nlm.nih.gov/33679717/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1bQr69UjXVaRRUWkFKIzHYhAULOEOHnEnNj24W3oISCxcPMYuA&fc=None&ff=20210308072436&v=2.14.2

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882449/

https://pubmed.ncbi.nlm.nih.gov/33603422/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1bQr69UjXVaRRUWkFKIzHYhAULOEOHnEnNj24W3oISCxcPMYuA&fc=None&ff=20210223145140&v=2.14.2

TITLE:
Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus

DESCRIPTION:
Type 1 diabetes mellitus (T1DM) results from the immune cell-mediated destruction of functional pancreatic β-cells. In the presymptomatic period, T1DM is characterized by the presence of two or more autoantibodies against the islet cells in patients without glycemic decompensation. Therapeutic strategies that can modify the autoimmune process could slow the progression of T1DM. Dipeptidyl peptidase-4 (DPP-4) or CD26, a multifunctional serine protease with a dual function (regulatory protease and…

PMID:
pubmed:33603422

DATE FOUND:
02/23/21 05:54PM

LINK / URL:
https://pubmed.ncbi.nlm.nih.gov/33603422/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1bQr69UjXVaRRUWkFKIzHYhAULOEOHnEnNj24W3oISCxcPMYuA&fc=None&ff=20210223145140&v=2.14.2

Transforming type 1 diabetes: the next wave of innovation

https://link.springer.com/article/10.1007/s00125-021-05396-5

https://pubmed.ncbi.nlm.nih.gov/33550440/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1bQr69UjXVaRRUWkFKIzHYhAULOEOHnEnNj24W3oISCxcPMYuA&fc=None&ff=20210223145140&v=2.14.2

TITLE:
Transforming type 1 diabetes: the next wave of innovation

DESCRIPTION:
The discovery of insulin in 1921 enabled pharmaceutical production of animal insulins for the treatment of people with type 1 diabetes by 1922. The last several decades have witnessed enormous scientific progress in the therapy of type 1 diabetes, yet some developments have been incremental, and insulin is not a cure. Herein, I highlight key scientific advances potentially poised to improve the quality of life and treatment outcomes in type 1 diabetes. These innovations range from newer insulin…

PMID:
pubmed:33550440

DATE FOUND:
02/24/21 03:11AM

LINK / URL:
https://pubmed.ncbi.nlm.nih.gov/33550440/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1bQr69UjXVaRRUWkFKIzHYhAULOEOHnEnNj24W3oISCxcPMYuA&fc=None&ff=20210223145140&v=2.14.2

Harnessing CD8(+) T-cell exhaustion to treat type 1 diabetes

https://pubmed.ncbi.nlm.nih.gov/33548057/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1bQr69UjXVaRRUWkFKIzHYhAULOEOHnEnNj24W3oISCxcPMYuA&fc=None&ff=20210223145140&v=2.14.2

TITLE:
Harnessing CD8(+) T-cell exhaustion to treat type 1 diabetes

DESCRIPTION:
Although immune interventions have shown great promise in type 1 diabetes mellitus (T1D) clinical trials, none are yet in routine clinical use or able to achieve insulin independence in patients. In addition to this, the principles of T1D treatment remain essentially unchanged since the isolation of insulin, almost a century ago. T1D is characterized by insulin deficiency as a result of destruction of insulin-producing beta cells mediated by autoreactive T cells. Therapies that target beta-cell…

PMID:
pubmed:33548057

DATE FOUND:
02/24/21 03:35AM

LINK / URL:
https://pubmed.ncbi.nlm.nih.gov/33548057/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1bQr69UjXVaRRUWkFKIzHYhAULOEOHnEnNj24W3oISCxcPMYuA&fc=None&ff=20210223145140&v=2.14.2

Microencapsulation for the cell and molecular therapy of type 1 diabetes mellitus: actual state and future perspectives between promise and progress

https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.13372

https://www.ncbi.nlm.nih.gov/pubmed/32700473?dopt=Abstract

TITLE:
Microencapsulation for the cell and molecular therapy of type 1 diabetes mellitus: actual state and future perspectives between promise and progress.

DESCRIPTION:
Related Articles

Microencapsulation for the cell and molecular therapy of type 1 diabetes mellitus: actual state and future perspectives between promise and progress.

J Diabetes Investig. 2020 Jul 22;:

Authors: Basta G, Montanucci P, Calafiore R

Abstract

The history of microencapsulation of live cells starts from an old idea of Thomas M. S. Chang in 1964, thereafter applied to isolated pancreatic islets by Anthony M. Sun in 1980. The original aim was to provide isolated cells with an immune-protective shield, to prevent physical contact between the transplanted cells and the host’s immune system, with retention of the microcapsules’ biocompatibility and physical-chemical properties over time. In particular, this revolutionary approach essentially applied to islet grafts, in diabetic not immunosuppressed recipients, at pre-clinical (rodents), and subsequently clinical level. Among the different chemistries potentially suitable for microencapsulation of live cells, alginic acid (AG)-based polymers, originally proposed by Sun, proved to be superior to all others, in the following decades. In fact, only AG-based microcapsules, containing allogeneic islets, ultimately entered pilot human clinical trials in patients with type 1 diabetes mellitus, since immuno-selectiveness and biocompatibility of AG-hydrogels were never matched by other biopolymers. With problems related to human islet procurement coming into a sharper focus, in conjunction with technical limits of the encapsulated islet grafting procedures, new challenges are actually being pursued, with special regard to developing both, new cellular systems, able to release immunomodulatory molecules and insulin itself, and new microencapsulation methods, with use of novel polymeric formulations, under actual scrutiny. Use of embryonic and adult stem cells, within microcapsules, should address the restricted availability of cadaveric human donor-derived islets, while a new generation of newly-engineered microcapsules could better fulfil issues with graft site and long-term retention of biopolymer properties.

PMID: 32700473 [PubMed – as supplied by publisher]

PMID:
PubMed:32700473

DATE FOUND:
07/24/20 06:33AM

LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32700473?dopt=Abstract

Back to top